First Trust Capital Strength ETF
FTCSDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 30, 2026 | $0.26 | 2026-06-25 | 2026-06-25 |
| March 31, 2026 | $0.29 | 2026-03-26 | 2026-03-26 |
| December 31, 2025 | $0.26 | 2025-12-12 | 2025-12-12 |
| September 30, 2025 | $0.25 | 2025-09-25 | 2025-09-25 |
| June 30, 2025 | $0.23 | 2025-06-26 | 2025-06-26 |
Dividends Summary
- Consistent Payer: First Trust Capital Strength ETF has rewarded shareholders with 64 dividend payments over the past 18 years.
- Total Returned Value: Investors who held FTCS shares during this period received a total of $12.34 per share in dividend income.
- Latest Payout: The most recent dividend of $0.26/share was paid 18 days ago, on June 30, 2026.
- Yield & Schedule: FTCS currently pays dividends quarterly with an annual yield of 1.10%.
- Dividend Growth: Since 2008, the dividend payout has grown by 73.4%, from $0.15 to $0.26.
Company News
First Trust Canada announced the cap (17.23% gross), buffer (10%), and dates (May 19, 2026 – May 21, 2027) for the next Target Outcome Period of the MAYB.F ETF. The fund, managed by Vest Financial LLC, seeks to provide returns matching the S&P 500 up to a cap while buffering against losses.
Walkner Condon Financial Advisors LLC increased its holding in First Trust Capital Strength ETF (FTCS) by 41,581 shares worth $3.84 million in Q4 2025, making it the firm's 10th-largest holding at 2.26% of AUM. The ETF tracks well-capitalized U.S. companies and has delivered 7% returns over the past year with lower volatility than the S&P 500.
Ergawealth Advisors sold 81,378 shares of the First Trust Capital Strength ETF (FTCS) for approximately $7.52 million in the fourth quarter. The sale reflects investor shift away from defensive equity strategies toward higher-yielding investments, as FTCS gained only 7% over the past year, trailing the S&P 500 by about 7 percentage points. The fu...
Dover reported mixed Q1 results, with revenue slightly missing estimates but adjusted EPS beating. The company lowered its 2025 EPS guidance, leading to a premarket stock decline. Dover noted strength in secular-growth markets like single-use biopharma components, thermal connectors, and CO2 systems.
